YEAR EVENTS 1958 - The Company was incorporated on 26th April, as a private limited company under the name Kopran Chemical Company Pvt. Ltd. by Shri Ramanlal V Shah, Sevantilal A Shah, Chimanlal G Sheth and Jivanalal M Shah in 1972, the Company's management was acquired by Chemo Pharma Laboratories Ltd and the Company's products were marketed by them. 1984 - The Company was converted into a public limited company on 24th August. 1985 - In a special purpose antibiotic bulk drug Cephlaxin Monohydrate and an anti-TB formulation Rifampicin were launched in technical co-operation with Yuhan Corporation, South Korea to Support its expanding product base the Company integrated backwards into manufacture of 6APA a raw material required for bulk drug production. 1990 - The Company changed its name to Kopran Limited on 22nd August. - The Company is engaged in the manufacture of pharmaceuticals and bulk drugs. Originally the Company manufactured medical formulations with production of bulk drugs and drug intermediates being introduced in 1983. - The Company has built up its strengths in the production of a wide range of semi-synthetic Penicillins such as Ampicillin trihydrate, Cloxacillin Sodium and Amoxycillin Trihydrate in addition to producing several other bulk drugs and formulations prominent amongst which are VENT, ATEN, TINI 300, BREN 400 and Dilgina. 1992 - The Company was amongst the first to launch a new concept in the treatment of ulcers-Omeprazole under the brand name of LOKIT. - The company has been one of the promoters of Pharmacuetical Business Group (India) Ltd. a company which has been promoted along with M/s Lyka Laboratories Ltd., Themis Chemicals Ltd., Cadila Laboratories Ltd. and Anant & Co. to acquire the management of Gujarat Themis Biosyn Ltd.- a company manufacturing basic drugs from fermentation. - In November, the company issued for public subscription 16,00,000 equity shares of Rs 10/- each at a premium of Rs 80/- per share aggregating Rs 1440 lakhs and subsequent to that the capital was increased to Rs 8,00,00,000. 1993 - The company has once again won the second award for export performance for the year 1991-92 from CHEMEXCIL. 1994 - The Company promoted two subsidiaries, viz., Kopran International in United Kingdom and Kopran (H.K.) based in HongKong. - The Company have been rewarded by two esteemed awards received during 1993 viz., Indian Drug Manufacturers Association's QUALITY EXCELLENCE AWARD 1993 and the EUROPE QUALITY AWARD - 1993. 1995 - The Company issued Bonus Equity Shares in the ratio of 1:2, thereby increasing the Capital by Rs. 4.00 crores. 1996 - The Company has received the TRISHUL Award under the Large Scale Manufacturer category from CHEMEXCIL and Certificate of Merit from the Ministry of Commerce. - The Company has launched various new products like TRASIC (Tramadol - a potent analgesic). SOLOFLOX (Lomefloxacin - a new anti-bacterial), ZIMAT (Cetirizine - an anti-allergic) apart from various brand extensions and newer combinations. 1997 - The company launched various new products like AZ-1 Caps. Klodip Tabs, Moclox Kid Tabs, Amyn Kid Tabs, Tini-NF, Amyn Caps, Amyn Dry Syrup. - The company entered into a joint venture with M/s. Industrial Promotion Services Ltd. (a subsidiary of the Aga Khan Fund for Economic Development) to take over a running unit viz. Kampala Pharmaceutical Industries (1996) Ltd, in Uganda. - Kopran Limited has won for the fourth time in a row, the IDMA Award for Quality Excellence - Kopran Ltd, the second largest manufacturer of semi-synthetic penicillins in the world. - Kopran Ltd has entered into a memorandum of understanding (MoU) with Pharmacare Ltd to set up a 50:50 joint venture project for the manufacture of penicillin-based products in South Africa. 1998 - Kopran Drugs Ltd and Synpac Pharmaceuticals Ltd (UK) have entered into a strategic alliance whereby Synpac will be a primary supplier of penicillin G to Kopran Drugs Ltd and shall buy back Penicillin based products from Kopran Drugs for the international market. - Kopran Ltd has set up a dedicated marketing division for the same, under Kresp. 1999 - Kopran Drugs Ltd, set up under a strategic alliance with the UK-based Synpac Pharmaceuticals. - Kopran is re-examining its diagnostics tie-up with US-based Chiron Diagnostics following the latter's proposed global takeover by Bayer Diagnostics. - Kopran Ltd is setting up a pharmaceutical company in Dubai in association with Dubai Investments PJSC (Public Joint Stock Company). - Kopran has a state-of-the-art formulations plant at Sarvoli, which is expected to stand the company in good stead for targeting export markets. - The UK-based Synpac Pharmaceuticals, a leading penicillin manufacturer, is set to become a joint venture partner in Kopran Drugs, the antibiotics division which was hived off from the fast growing Kopran Ltd. 2000 - Kopran Pharmaceuticals, associated with the popular Smyle brand, has introduced the `American Dreams' range of fine perfumes in India, under a distribution arrangement with a US-based company. - Kopran Pharmaceuticals to launch another umbrella brand along the lines of its flagship brand Smyle. - The Company has decided to issue equity shares to members, employees, NRIs, OCBs, FIIs, MFs, IFIs, companies and/or other entity/entities and to such other persons by way of public issue, rights issue preferential allotment or on private placement basis. - Kopran Pharmaceuticals has launched a range of digestive tablets branded Yum Tum. - KResp, a division of Kopran Ltd., has launched a new aerosol holding device, which is smaller in size called `Vent-Mate'. - Pharmaceuticals company Kopran Ltd has tied up with E Merck India for marketing Atorvastain, a new product in the anti-cholesterol segment, in India. - Kopran Ltd have fixed the swap ratio for the merger of group company Kopran Pharmaceuticals with it at 17:1. - Kopran Ltd is to issue 40 lakh equity shares at Rs 150 per share to shareholders of group company Kopran Pharmaceuticals Ltd, as part of the merger. 2001 - The Company has tied up with E Merck Ltd for a co-marketing arrangement for a new antiinflammatory oranalgestic drug Rofecoxib, for the Indian market. - Kopran Ltd. is launching Dr Smyle Prickly Heat Powder, in a pack of 150g. - Kopran Ltd, the Rs 900 crore pharma major, has sold the marketing rights for its anti-hypertensive drug 'Aten' to Zydus Cadila for a consideration of Rs 75 crore. 2002-Kopran Ltd has informed BSE that Mr Humayun Dhanrajgir has resigned from Directorship. 2003 -Receives approval from the patent office of the US for its new chemical entity (NCE), KNC-6 -Received an approval for restructuring its high cost debts from the Corporate Debt Restructuring (CDR) Cell. The key highlights of this restructuring is as follows: 1. The rates of interest both on long term debts and the working capital borrowing would come down from the current 13.50% to 9% leading to significant reduction of the interest cost. 2. The repayments of long-term debts have been rescheduled to be paid by 2009. 3. Release of additional working capital to meet requirements of the planned growth in business. - HSBC Financial Services has acquired a 6.06 per cent stake in Kopran Pharmaceuticals, taking its holding in the Mumbai-based pharmaceutical company to 10.01 per cent. -Kopran receives approval from EDQM for its API facility at Mahad 2004 Kopran Ltd has informed that The Stock Exchange Ahmedabad (ASE) vide letter dated April 08, 2004 have delisted the shares of the Company w.e.f. April 08, 2004. -Merrill Lynch Capital Markets Espana SA SV, has acquired an 8.49 per cent stake in drug maker Kopran through the open market -Kopran Ltd has informed that at the meeting of the BoD of the company held on July 31, 2004, Board has recorded and accepted the resignation of Mr. Tapan Ray, Managing Director of the company with effect from October 31, 2004 2005 - The Company has appointed Mr.H.P.Vyas as Company Secretary. - The Company has entered into a Strategic Alliance with Merck Specialities Pvt Ltd. 2006 - The company has signed a distribution pact with Mumbai-based Manish Pharma for its complete range of over the counter (OTC) products. 2011 - The company has appointed Mr. Abhinav Mathur as a Company Secretary & Compliance Officer. 2013 - Kopran Ltd. is launching a new brand "SPARKLE" in the FMCG category.The first product which would be launched would be Toothpaste, followed by various other products". 2018 -"Kopran Research Laboratories Limited, a wholly owned subsidiary of the Company purchased API facility at Panoli , Gujarat".